Albireo to participate in jefferies london healthcare conference

Boston, nov. 09, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the jefferies london healthcare conference in london, uk, from november 15-17, 2022. simon harford, chief financial officer of albireo, will be presenting on november 15, 2022, at 10:20 am gmt.
ALBO Ratings Summary
ALBO Quant Ranking